Ceramide-mediated gut dysbiosis enhances cholesterol esterification and promotes colorectal tumorigenesis in mice.
Ceramide-mediated gut dysbiosis enhances cholesterol esterification and promotes colorectal tumorigenesis in mice.
复制标题
神经酰胺介导的肠道菌群失调增强胆固醇酯化并促进小鼠结直肠肿瘤的发生
DOI:
10.1172/jci.insight.150607
复制
发表时间:
2022-02-08
期刊:
影响因子:
8
通讯作者:
Li Y
中科院分区:
文献类型:
--
作者:
Zhu Y;Gu L;Lin X;Zhang J;Tang Y;Zhou X;Lu B;Lin X;Liu C;Prochownik EV;Li Y
Colorectal cancer (CRC) severely threatens human health and life span. An effective therapeutic strategy has not been established because we do not clearly know its pathogenesis. Here, we report that ceramide and sterol O-acyltransferase 1 (SOAT1) have roles in both spontaneous and chemical-induced intestinal cancers. We first found that miRNA-148a deficiency dramatically increased mouse gut dysbiosis through upregulating ceramide synthase 5 (Cers5) expression, which promoted ceramide synthesis afterward. The newly generated ceramide further promoted both azoxymethane/dextran sodium sulfate–induced (AOM/DSS-induced) and ApcMin/+ spontaneous intestinal tumorigenesis via increasing mouse gut dysbiosis. Meanwhile, increased level of ceramide correlated with the significant enhancements of both β-catenin activity and colorectal tumorigenesis in a TLR4-dependent fashion. Next, we found a direct binding of β-catenin to SOAT1 promoter to activate transcriptional expression of SOAT1, which further induced cholesterol esterification and colorectal tumorigenesis. In human patients with CRC, the same CERS5/TLR4/β-catenin/SOAT1 axis was also found to be dysregulated. Finally, the SOAT1 inhibitor (avasimibe) showed significant levels of therapeutic effects on both AOM/DSS-induced and ApcMin/+ spontaneous intestinal cancer. Our study clarified that ceramide promoted CRC development through increasing gut dysbiosis, further resulting in the increase of cholesterol esterification in a SOAT1-dependent way. Treatment with avasimibe to specifically decrease cholesterol esterification could be considered as a clinical strategy for effective CRC therapy in a future study.
登录
查看更多内容
影响因子:
3.7
作者:
Ayyagari, Vijayalakshmi N.;Wang, Xinjia;Brard, Laurent
通讯作者:
Brard, Laurent
DOI:
10.1002/cjp2.5
发表时间:
2015-01
期刊:
The journal of pathology. Clinical research
影响因子:
--
作者:
Fitzgerald S;Sheehan KM;Espina V;O'Grady A;Cummins R;Kenny D;Liotta L;O'Kennedy R;Kay EW;Kijanka GS
通讯作者:
Kijanka GS
影响因子:
3.9
作者:
Cleary, Joseph M.;Lipsky, Zachary W.;German, Guy K.
通讯作者:
German, Guy K.
影响因子:
8.8
作者:
Hu S;Peng L;Kwak YT;Tekippe EM;Pasare C;Malter JS;Hooper LV;Zaki MH
通讯作者:
Zaki MH
DOI:
10.1084/jem.20120239
发表时间:
2012-07-02
期刊:
The Journal of experimental medicine
影响因子:
--
作者:
Boulard O;Kirchberger S;Royston DJ;Maloy KJ;Powrie FM
通讯作者:
Powrie FM